In this work, UiO-66-NH2 was used to prepare a new delivery system by incorporating copper sulfide (CuS) into the pores. The CuS nanoparticles (NPs) were prepared to enhance the anticancer effects of Oxaliplatin (OXA) against colorectal cancer. The oxaliplatin was loaded into CuS@UiO-66-NH2. To characterize and investigate their cytotoxicity effects, powder X-ray diffraction (PXRD), Fourier transformation infrared spectroscopy (FT-IR), Brunauer–Emmett–Teller (BET) analysis, UV-Visible analysis, inductively coupled plasma mass spectrometry (ICP-MS), and MTT assay were considered to be performed. According to the observations, the cytotoxicity of OXA-CuS@UiO-66-NH2 was greater than that of the OXA alone.

In this study, copper sulfide nanoparticles (CuS‐NPs), which can improve the antiproliferative properties of conventional anticancer drugs such as 5‐fluorouracil (5‐FU), were incorporated into the pores of amine‐functionalized UiO‐66 (CuS/NH2‐UiO‐66). The introduced nano‐drug delivery system was exerted to perform an in vitro treatment on CT‐26 mouse colorectal cancer cells. The synthesized final product was labeled as 5‐FU@CuS/NH2‐UiO‐66 and characterized through conventional methods including X‐ray diffraction (XRD), Fourier transformation infrared spectroscopy (FT‐IR), Brunauer–Emmett–Teller (BET) analysis, Ultraviolet‐Visible (UV‐Vis) analysis, Inductively coupled plasma mass spectrometry (ICP‐MS), and 3‐(4,5‐dimethylthiazol‐2‐yl)−2,5‐diphenyltetrazolium bromide (MTT) assay. In contrast to 5‐FU, the outcomes of the cytotoxicity assay lacked any comparable results for 5‐FU@CuS/NH2‐UiO‐66.

Background/aims: Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common form of colorectal cancer (CRC) syndrome, in which the mutations in mismatch repair genes have been implicated in the disease etiopathogenesis. The aim of this study was to investigate the prevalence of human mutL homolog 1 (hMLH1) gene point mutations in patients with HNPCC in Northwest of Iran. Methodology: In this study, 30 patients with HNPCC were selected who fulfilled the Amsterdam II criteria. Moreover, 30 subjects were selected as the control group. Total RNA was extracted from peripheral blood sample, and complementary DNA (cDNA) was synthesized using specific primers. Screening of germline mutations within the hMLH1 gene was performed by direct cDNA sequencing. Functional evaluation was conducted through real-time polymerase chain reaction mRNA expression using the TaqMan Gene Expression Assay. Results: In this study, c.655A >G polymorphism was found in 13.3% of patients and 10% of the control group, while c.1959G > T polymorphism was found in only one of the patients. Two novel variants, including c.973C > A and c.1086C > A, were found in 13.3% and 20% of patients, respectively, that were identified for the 1 st time in this study. Moreover, the mRNA expression of hMLH1 gene in patients carrying the c.973C > A and c.1086C > A mutations showed no statistically significant difference in comparison to patients with no mutation and healthy controls. Conclusions: This study establishes that the frequency and type of mutations do not follow a similar pattern in other populations due to genetic and geographical differences.